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Toxin A-negative, toxin B-positive strains (A–/Bþ) are the best studied examples of Clostridium difficile
variant strains. In addition, there are some other groups of variant C. difficile strains that produce both toxins
(Aþ/Bþ) or are non-cytotoxic (A–/B–) but differ from the reference strain VPI 10463 in their toxin
genes. Here we describe two simple methods (amplification of the tcdA gene and amplification of the binary
toxin gene cdtA) which can be used in rapid screening for variant C. difficile strains in collections or in
routine laboratories.
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INTRODUCTION
Clostridium difficile has been isolated in routine microbiology
laboratories since it was recognised as a potential pathogen in
the late 1970s [1]. Its main virulence factors are two large toxins
[toxin A (TcdA) and toxin B (TcdB)], and diagnostic tests rely
on culture and/or detection of one or both toxins. In recent
years, new features of C. difficile have been discovered, such as
variability in toxin A and B production, variability of toxin
genes for toxins A and B and production of a third toxin (binary
toxin CDT) by certain strains [2,3]. This paper will describe
how these new findings can be used in routine diagnostic
procedures.
It has long been accepted that toxigenic strains always
produce both toxins A and B and that non-toxigenic strains
do not posses toxin genes [4]. However, toxin A-negative, toxin
B-positive (A–/Bþ) strains have only been described recently
[5–7]. Such A–/Bþ strains are usually referred to as variant or
toxin-variant C. difficile strains. But differences in toxin pro-
duction is not the only variation among C. difficile isolates. Far
greater heterogeneity is observed when toxin genes for toxins A
and B are screened. We define toxin-variant strains as those
producing only toxin A or B (at present only A–/Bþ toxin-
variant strains are known), and variant strains are all the C.
difficile strains characterised by changed toxin genes tcdA and
tcdB when compared to the reference strain VPI 10463 [8].
Therefore, toxin-variant strains are only one group of variant
C. difficile strains.
Changes within toxin genes are deletions, detected only in
repetitive regions of the tcdA gene, or restriction site poly-
morphisms, which are observed in both toxin genes (Table 1).
In terms of toxin production, variant strains can produce both
toxins (Aþ/Bþ strains), only TcdB (A–/Bþ strains), or are
non-cytotoxic but still possess parts of the toxin genes (A–/B–
strains) (Table 1) [3,9]. Variant C. difficile strains are grouped into
toxinotypes I–XV, whereas strains similar to VPI 10463 belong
to toxinotype 0 [8,9].
HOW TO DETECT C. DIFFICILE VARIANT STRAINS
Methods for laboratory diagnosis of C. difficile usually depend
on isolation of pure culture as well as on detection of toxin
production on cultured cells or with commercial immunolo-
gical tests [1]. Such methods would correctly diagnose the
majority of variant strains as C. difficile. However, with classical
methods, variant strains (with changes in toxin genes) cannot be
distinguished from VPI 10463-like strains (Table 2). If only a
commercial toxin A-detecting diagnostic kit is used, strains
from toxinotypes VIII and X (producing only toxin B) and
toxinotype XI (non-cytotoxic) are not even detected. On the
other hand, A–/Bþ strains (toxinotypes VIII and X) are the only
variant strains recognised if a combination of cell culture test
(with positive result) and immunological test (with negative
result) is used (Table 2).
Detection of variant strains in the clinical laboratory can be
based on differences between variant strains (toxinotypes I–XV)
and ordinary (toxinotype 0) strains. As mentioned above,
variant strains can differ from ordinary strains in: (i) production
of toxins TcdA and TcdB, (ii) toxin genes tcdA and tcdB, and (iii)
production of binary toxin (Table 1).
Relying solely on differences in toxin production, only two
toxinotypes (VIII and X), representing A–/Bþ strains, will be
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recognised. Here we should mention that cell culture tests can
be helpful in determining variant strains. It is well known that
some C. difficile variant strains (1470, 8864) cause different
cytopathic effects when compared with ordinary strains [10–
12]. Usually, cells treated with supernatants containing C.
difficile toxins detach, but retain long projections (actinomorphic
morphology). Strains from toxinotypes VIII and X (both A–/
Bþ) and IX (Aþ/Bþ) cause cell rounding without projections.
Thus, if the cell culture test is read carefully, some groups of
variant C. difficile strains can be recognised. It is recommended
that each laboratory tests its own cell line with culture super-
natants of VPI 10463 and 8864 (type strain for toxinotype X) or
1470 (type strain for toxinotype VIII).
Most of the variant toxinotypes will be recognised if the toxin
genes for TcdA and TcdB are screened. There are many PCRs
described for amplification of some parts of C. difficile toxin
genes and some of them also detect variations, mainly in tcdA
[13,14]. We have described a PCR method for amplification of
the entire 19 kb of PaLoc with 10 overlapping PCR fragments
[8], and we have shown that two of those PCR fragments are
mostly variable (B1 and A3) and are good markers when
searching for variant strains (Table 1). The PCR method is
described in detail in references [8,15] and on our toxinotyping
home-page (http://www.uni-lj.si/bfbcdiff). One can use
only one of the PCRs or both of them. If both PCR fragments
are tested, then the tested strain is not only recognised as a
variant, but can already be grouped in one of the 15 toxino-
types. With this method, all known and potential new types of
variant strains are recognised. The drawback of the method is
that it requires long PCR programs of about 6 h and must be
combined with restriction analysis. If only one region of the
toxin genes for TcdA and TcdB is to be tested, then the most
suitable part is the repetitive region of tcdA (amplified in A3
PCR fragment) because this part is changed in most toxinotypes
(Table 1). The only exception is toxinotype XII, which has
changes only in the tcdB gene. A3 PCR fragment will not be
amplified in strain 8864 (toxinotype X) and, if production of
toxin B is not tested, this type of strain will not be detected.
Table1 Differences between reference C. difficile strainVPI10463 and variant strains
Changes in tcdB and tcdA genesa
Toxinotype B1 B2 B3 A1 A2 A3
Production of
LCT toxins
Production of
binary toxin
0 0 0 0 0 0 0 Aþ/Bþ ^
I, II, XIII 0 0 0 0 0 R Aþ/Bþ ^
XII R 0 0 0 0 0 Aþ/Bþ ^
XI a/b na na na na R D A^/B^ þ
III, IV,V,VI,
VII,VIII, IX,
X, XIV, XV
R R R R R Ror D Aþ/Bþ
or
A^/Bþ (VIII, X)
þ
a0, length and restrictionpatterns of amplified PCR product are the same as in strainVPI10463; R, RFLP detected in amplified fragment; D, deletion detected in
amplified fragment; na, PCR fragment can not be amplified. aPCR fragments B1^B3, A1^A3 according to reference [8].
Table 2 Effectivenes of different diagnostic tests in detection of variant toxinotypes
C. difficile detected C. difficile not detected
Diagnostic test Recognised toxinotypes Not recognised toxinotypesa Toxinotypes not detected
Diagnostic immunological kit
(toxin A only)
None All
(notVIII, X, XI)
VIII, X, XI
Diagnostic immunological kit
(toxin A and B)
None All
(not XI)
XI
Cell culture test and
immunological kit for toxin A
VIII, X I^VII, IX,
XI^XV
B1and A3 PCRand restriction All
A3 PCRand restriction
(repetitive region of tcdA gene)
I, II, III, IV,V,
VI,VII,VIII, IX,
X, XI, XIV, XV
XII (Xb)
PCR
(binary toxin genes)
III, IV,V,VI,VII,
IX, X, XI, XIV, XV
I, II, XII, XIII,
VIII
aRecognised as C. difficile, but not as a variant strain; bA3 amplification is negative in toxinotype X.
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However, to date only a single isolate of toxinotype X is known,
although another three similar strains were recently found
[16, M. Rupnik and H. Kato, unpublished data] and it seems
that this type of variant strain is rather rare.
Checking only the A3 PCR fragment allows recognition of
13 out of 15 known variant toxinotypes and, although less
laborious than amplification of both fragments (B1 and A3), it is
still time-consuming.
For screening that is applicable in routine laboratories, a
quick and easy method is needed which would still recognise
the most important variant toxinotypes, i.e. the detection of
binary toxin genes. The majority of strains with changes in
genes tcdA and tcdB (variant strains) will produce a binary toxin
(Table 1) [3]. To date, no strain from toxinotype 0 (VPI 10463-
like strains) has been binary toxin-positive. When amplification
of binary toxin genes is used as a screening method, 10 out of 15
toxinotypes can be detected (Table 2). This method is less
effective than amplification of the A3 PCR fragment described
above, but is easier and less time-consuming. Toxinotypes not
possessing binary toxins (I, II, XII, XIII, VIII) are not sig-
nificantly changed in their toxin genes or are A–/Bþ strains
(Table 1).
There are two binary toxin genes (cdtA and cdtB) coding for
two components of the binary toxin. Variant strains studied to
date have both genes but it seems that amplification of cdtB is
more efficient [3]. We would suggest PCR amplification of part
of the cdtB gene (described in detail on our toxinotyping home
page and in reference [3]) as a method of choice for quick
detection of variant C. difficile strains because: (i) it is easy to
perform, (ii) it does not include restriction of the amplified
fragment and is therefore less time-consuming, and (iii) it would
detect the majority of variant strains with significantly changed
toxin genes. Still, positive amplification of binary toxin genes
only shows that the tested strain is most probably a variant. To
assign it to a given toxinotype, toxinotyping (characterisation of
B1 and A3 fragments) must be performed.
WHY IS DETECTION OF C. DIFFICILE VARIANT
STRAINS IMPORTANT?
Based on the studies of two large C. difficile collections [8,9], the
prevalence of variant strains within the C. difficile population
was calculated to be approximately 8%. But the clinical impor-
tance of C. difficile variant strains is unknown because they are
not recognised as special subgroups of C. difficile. Similarly, the
A–/Bþ strains have been largely underestimated because such
strains have not been recognised in diagnostic laboratories.
Their role in causing severe disease and outbreaks was clarified
only recently [17–19].
Variant C. difficile strains can be searched for in established
strain collections or directly in routine laboratories as a part of
C. difficile diagnostics. Strain collections previously typed with
one of the molecular typing methods are most suitable, as the
presence of variant toxin genes correlates well with molecular
typing [9]. With such studies, the overall prevalence of variant
strains will be determined and most probably some new types of
variant C. difficile strains will be discovered. This is also a way to
see if some variant C. difficile strains are more prevalent in certain
hosts. In animals, C. difficile can cause intestinal diseases as well,
and a high percentage of binary toxin-positive strains (which are
most probably variant C. difficile strains) was reported in horses,
whereas such strains were not detected in dogs or cats [20].
Detection of variant strains in routine diagnostic laboratories
should provide useful information on the prevalence of different
toxinotypes within a given hospital at a given time. Most
importantly, this is the only way to find a possible connection
between variant strains and special patient populations or forms
of the disease because, when a strain is identified as a variant,
additional data about the symptoms (which usually are not
available for collection strains) can be obtained.
There are several reasons why different toxinotypes can be
expected to correlate with different forms of the disease or
different populations. One reason is the production of variant
toxins with changed properties by variant strains. For some
strains, it has already been shown that the toxins they produce
differ from VPI 10463 toxins in catalytic properties [12,21].
Likewise, we can expect variant toxins to differ in translocating
or receptor-binding, which can determine host or tissue spe-
cificity. The observation that most variant strains produce at
least one additional virulence factor not detected in ordinary
strains, namely binary toxin [3], supports the speculation of the
clinical importance of variant strains. Typically, in other clos-
tridial species (e.g. C. perfringens and C. novyi), groups of strains
produce certain combinations of toxins. These toxin-produc-
tion types are then predominant in different hosts or in different
forms of the disease. To date, C. difficile has been regarded as
producer of only two major toxins (TcdA and TcdB). With the
identification of binary toxin-producing strains, C. difficile
strains can also be distributed into five toxin production types
(Table 1) [3]. But the connection between these types and
certain diseases remains to be discovered.
Detection of binary toxin genes would not only aid the
identification of variant strains but would also help to elucidate
the role of some non-toxigenic (A–/B–) strains isolated from
symptomatic patients. Strains that do not produce TcdA and
TcdB were regarded as non-virulent, but we have shown that
some non-cytotoxic strains can produce a binary toxin (tox-
inotype XI) [3] which could then act as a potential virulence
factor.
In this paper, two PCR-based methods are described which
can be used not only for recognition of A–/BþC. difficile strains
but also for detection of variant A–/B– and Aþ/Bþ strains.
Information on the prevalence of variant strains and their clini-
cal importance can be obtained using these methods. Screening
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with binary toxin PCR can provide additional information on
the prevalence of binary toxin-producing C. difficile and its
significance in toxinogenic and non-toxinogenic strains.
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